Beximco Pharmaceuticals PLC has reported a 13.1 percent year-on-year increase in revenue for the first nine months of the 2025-26 financial year, outperforming major competitors in the Bangladeshi pharmaceutical sector.
The company recorded net revenue of Tk 4,142 crore during the July-March period, up from Tk 3,662 crore in the same period last year.
The growth trajectory highlights Beximco's ability to maintain market share and expand sales volumes despite broader industry pressures.
This performance stands in contrast to several key peers, reinforcing Beximco's position as a dominant player in the local market.
The revenue beat suggests strong demand for the company's generic drug portfolio and potentially effective pricing strategies in a price-sensitive environment.
Investors will be watching for the full-year results to see if this momentum continues into the final quarter.